Claude Lemarie

Institut Paoli Calmettes, Marsiglia, Provence-Alpes-Côte d'Azur, France

Are you Claude Lemarie?

Claim your profile

Publications (35)83.06 Total impact

  • Bone marrow transplantation. 07/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In the attempt to harmonize clinical practices between different French transplantation centers, the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC) set up its fourth annual series of workshops which brought together practitioners from all of its member centers. These workshops took place in September 2013 in Lille. Literature and intra-laboratories studies suggest that attached segment is representative of cord blood unit (CBU). Nevertheless, some discrepancies have been observed when analyzing large data registries. To address these issues, we have listed recommendations to increase the standardization of segment processing and quality control (QC), information on units of measurement and specifications and action to be taken in case of out of specifications QC results on segment.
    Pathologie Biologie 07/2014; · 1.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is recommended for patients with high-risk AML. In many situations, a matched-related (MRD) or matched-unrelated donor (MUD) is lacking, in which case unrelated cord blood units (UCB) provide an alternative. We analyzed the outcome of consecutive high-risk AML patients prepared with reduced intensity conditioning (RIC) regimens and allografted with UCB (n = 32) compared their outcome with high risk-AML patients transplanted with MRD/MUD (n = 49) in the same period of time. Grade III-IV acute graft-versus-host disease (GVHD) occurred slightly more frequently in the UCB group (25%) than in the MRD/MUD group (8%) (p = 0.069). Conversely, we found a lower incidence of extensive chronic GVHD in the UCB group (6%) than in the MRD/MUD group (20%, p = 0.085). NRM at 4 years was 16% and 22% in the UCB and MRD/MUD groups, respectively (p = 0.529). The cumulative incidence of relapse at 4 years was significantly higher in the UCB group (60%) than in the MRD/MUD group (27%, p = 0.006). Leukemia free survival (LFS) and overall survival (OS) at 4 years were 25% and 34%, respectively, in the UCB group and 50% and 56%, respectively, in the MRD/MUD group (LFS, p = 0.029; OS, p = 0.072). Multivariate analyses adjusted by cytogenetics and disease status at the time of Allo-HSCT revealed that use of UCB remained an independent predictive factor of shorter LFS (HR: 2.0 [1.1-3.6], p = 0.018), and was associated with a trend for shorter OS (HR: 1.7 [0.9-3.2], p = 0.093). While UCB provides an alternative for patients with high-risk AML lacking a MRD/MUD, the high incidence of relapse after RIC-based UCB Allo-HSCT is a concern. Attempts to improve leukemic control with UCB Allo-HSCT are warranted, as well as the evaluation of other alternative donors in this context.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 06/2014; · 3.15 Impact Factor
  • Bone marrow transplantation. 06/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Regulation (EC) n° 1394/2007 from the European Parliament and the Council describes a new category of health products termed « Advanced Therapy Medicinal Products » (ATMPs). ATMPs derive from cell engineering, tissue engineering or genetic manipulations, and can in some instances be combined with medical devices. ATMPs are distributed and administered to patients, after biotechnology or pharmaceutical companies have obtained a marketing authorization that is granted by the European Commission on the basis of the European Medicines Agency (EMA) assessment. Seven years after the publication of the regulation, few of these therapies have received a marketing authorization, and even fewer have met commercial success, suggesting that a number of medical and economic issues still need to be sorted out in order to achieve sustainability in this field. The coexistence of three sets of rules for three categories of health products that are biologically and medically related - ATMPs, ATMPs produced under the hospital exemption rule, and cell therapy products (CTPs) (a specific legal category in France) that have long been used in hematopoietic cell transplantation - constitutes a complex regulatory framework. This situation raises significant issues for historical as well as emerging operators in this moving field that are discussed thereafter.
    Médecine sciences : M/S. 05/2014; 30(5):576-83.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In 2005, the National Institutes of Health (NIH) proposed standard criteria for diagnosis, organ scoring and global assessment of chronic graft-versus-host disease (cGvHD) severity. We retrospectively reclassified cGvHD with NIH criteria in a monocentric cohort of 130 consecutive adult patients with hematological malignancies presenting cGvHD after receiving allo-hematopoietic stem cell transplant (HSCT) with a fludarabine–busulfan–antithymocyte globulin (ATG) conditioning regimen, among 313 consecutive HSCT recipients. We compared NIH and Seattle classifications to correlate severity and outcome. The follow up range was effectively 2–120 months. Forty-four percent developed Seattle-defined cGvHD (22% limited, 78% extensive forms). Using NIH criteria, there were 23%, 40% and 37% mild, moderate and severe forms, respectively, and 58%, 32% and 8% classic cGvHD, late acute GvHD and overlap syndrome. Five-year overall survival was 55% (49–61), and cumulative incidences of non-relapse mortality (NRM) and relapse/progression at 2 years were 19% (14–23) and 19% (14–24). NIH mild and moderate forms were associated with better survival compared to severe cGvHD (hazard ratio [HR] = 3.28, 95% confidence interval [CI]: 1.38–7.82, p = 0.007), due to higher NRM among patients with severe cGvHD (HR = 3.04, 95% CI: 1.05–8.78, p = 0.04) but comparable relapse risk (p = NS). In conclusion, the NIH classification appears to be more accurate in predicting outcome mostly by the reclassification of old-defined extensive forms into NIH-defined moderate or severe.
    Leukemia and Lymphoma 01/2014; 55(5). · 2.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is recommended for patients with high-risk AML. In many situations, a matched-related (MRD) or matched-unrelated donor (MUD) is lacking, in which case unrelated cord blood units (UCB) provide an alternative. We analyzed the outcome of consecutive high-risk AML patients prepared with reduced intensity conditioning (RIC) regimens and allografted with UCB (n = 32) compared their outcome with high risk-AML patients transplanted with MRD/MUD (n = 49) in the same period of time. Grade III–IV acute graft-versus-host disease (GVHD) occurred slightly more frequently in the UCB group (25%) than in the MRD/MUD group (8%) (p = 0.069). Conversely, we found a lower incidence of extensive chronic GVHD in the UCB group (6%) than in the MRD/MUD group (20%, p = 0.085). NRM at 4 years was 16% and 22% in the UCB and MRD/MUD groups, respectively (p = 0.529). The cumulative incidence of relapse at 4 years was significantly higher in the UCB group (60%) than in the MRD/MUD group (27%, p = 0.006). Leukemia free survival (LFS) and overall survival (OS) at 4 years were 25% and 34%, respectively, in the UCB group and 50% and 56%, respectively, in the MRD/MUD group (LFS, p = 0.029; OS, p = 0.072). Multivariate analyses adjusted by cytogenetics and disease status at the time of Allo-HSCT revealed that use of UCB remained an independent predictive factor of shorter LFS (HR: 2.0 [1.1–3.6], p = 0.018), and was associated with a trend for shorter OS (HR: 1.7 [0.9–3.2], p = 0.093). While UCB provides an alternative for patients with high-risk AML lacking a MRD/MUD, the high incidence of relapse after RIC-based UCB Allo-HSCT is a concern. Attempts to improve leukemic control with UCB Allo-HSCT are warranted, as well as the evaluation of other alternative donors in this context.
    01/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dans une démarche qui vise à uniformiser les procédures d’allogreffe de cellules souches hématopoïétiques (CSH), la Société française de greffe de moelle et de thérapie cellulaire (SFGM-TC) a organisé les quatrièmes ateliers d’harmonisation des pratiques en septembre 2013 à Lille. Cet atelier a été consacré au segment attaché des unités de sang placentaire dans le but d’établir des recommandations quant à la standardisation du traitement de ce segment et les mesures à prendre en cas de rupture de ce segment.
    Pathologie Biologie 01/2014; · 1.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We retrospectively analyzed outcomes of a CD34+-selected stem cell boost (SCB) without prior conditioning in 32 patients (m/22; median of 54 years; 20 - 69) with poor graft function defined as: neutrophils ≤1.5 x 109/L, and/or platelets ≤30 x 109/L, and/or hemoglobin ≤8.5 g/dL). The median interval between stem cell transplantation and SCB was 5 months (2 - 228). The median number of CD34+ and CD3+ cells were 3.4 x 106/kg (0.96 - 8.30) and 9 x 103/kg b.w. (2 - 70), respectively. Hematological improvement was observed in 81% of patients and noted after a median of 30 days (range 14 - 120) after SCB. The recipients of related grafts responded faster than those of unrelated grafts (20 vs. 30 days, p=0.04). The cumulative incidence of acute (grade II-IV) and chronic GvHD after SCB was 17% and 26%, respectively. Patients with acute GvHD received a higher median CD3+ cell dose. The 2-year probability of OS was 45%. We suggest that SCB represents an effective approach to improve poor graft function post-transplant, but optimal timing of SCB administration, anti-infective and GvHD prophylaxis needs further evaluation.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 12/2013; · 3.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Non-myeloablative (NMA) regimens allow extending allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in patients unfit for standard myeloablative conditioning (MAC) regimens using high dose alkylating agents with or without total body irradiation. Reduced intensity conditioning (RIC) regimens, based on fludarabine (Flu), busulfan, and rabbit antithymocyte globulin (r-ATG), represent an intermediate alternative between the NMA and MAC regimens. This platform was optimized over the years by the introduction of intravenous busulfan and the use of 5 mg/kg of r-ATG, with the hypothesis that these modifications could improve the safety of RIC Allo-HSCT. Here, we report a study conducted at our institution on 206 patients with a median age of 59 years, who received Allo-HSCT prepared using fludarabine, 2 days of intravenous busulfan and 5 mg/kg of r-ATG (FBx-ATG), between 2005 and 2012. Grade III-IV acute and extensive chronic graft-versus-host diseases (GVHD) were 9% and 22%, respectively. After 4 years, non-relapse mortality (NRM), relapse, and overall survival (OS) were 22%, 36%, and 54%, respectively. NRM tended to be influenced by comorbidities (HCT-CI < 3 vs. HCT-CI ≥ 3: 18% vs. 27%, p=0.075) but not by age (< 60 vs. ≥ 60 years: 20% vs. 25%, p=0.142). Disease risk significantly influenced relapse (2 years; low: 8%, intermediate: 28%, high: 34%, and very high: 63%, p=0.017). Both disease risk [Hazard ratio (95%CI); intermediate: 2.1 (0.8-5.2), p=0.127; high: 3.4 (1.3-9.1), p=0.013; very high: 4.0 (1.1-14), p=0.029] and HCT-CI [Hazard ratio (95%CI): HCT-CI ≥ 3: 1.7 (1.1-2.8), p=0.018] influenced OS, but not age or donor type. The FBx-ATG RIC regimen, as reported here, results in low mortality and high long-term disease-free survival, without persisting GVHD, in both young and old patients. It represents a valuable platform to develop further post-transplantation strategy aimed at reducing the incidence of relapse, particularly in the setting of high-risk diseases.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 12/2013; · 3.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Conditioning regimen including fludarabine (FLU), intravenous busulfan (Bx), and 5 mg/kg total dose of rabbit antithymocyte globulin (r-ATG) (FBx-ATG), results in low incidence of graft-versus-host disease (GVHD) and non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) from HLA-matched related or unrelated donors (MUD). However, whether this platform produces similar results in the setting of one mismatch unrelated donor (MMUD) Allo-HSCT is not known. We retrospectively analyzed patients aged less than 65 years who were diagnosed with hematological malignancies and received FBx-ATG regimen prior to Allo-HSCT from MUD (N=74) or MMUD (N=40). We compared outcome of MUD vs. MMUD patients. There was no difference in the cumulative incidence of grade II-IV acute GVHD (MUD: 34% vs. MMUD: 35%, p=0.918), but MMUD patients developed more grade III-IV acute GVHD (MUD: 5% vs. MMUD: 15%, p=0.016). The cumulative incidences of overall chronic GVHD (MUD: 33% vs. MMUD: 22%, p=0.088) and extensive chronic GVHD (MUD: 20% vs. MMUD: 19%, p=0.594) were comparable. One-year NRM was similar in both groups (MUD: 16% vs. MMUD: 14%, p=0.292); similarly, progression-free survival (MUD: 59% vs. MMUD: 55%, p=0.476) and overall survival (MUD: 63% vs. MMUD: 61%, p=0.762) were not different between both groups. With a median follow up of 24 months, 35 of 74 MUD patients (47%) and 19 of 40 MMUD patients (48%) were free of both disease progression and immunosuppressive treatment. We conclude that the FBx-ATG regimen results in low incidences of NRM and GVHD in both MUD and the MMUD recipients.
    American Journal of Hematology 09/2013; · 4.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the attempt to harmonize clinical practices between different French transplantation centers, the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC) set up the third annual series of workshops which brought together practitioners from all member centers and took place in October 2012 in Lille. Here we report our results and recommendations regarding the choice of optimal unrelated cord blood unit in terms of cell dose, HLA-matching and other characteristics.
    Pathologie Biologie 09/2013; · 1.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: New strategies are emerging in cord blood banking where focusing on birth clinics caring for a high number of mothers belonging to ethnic minorities could offer new possibilities for allotransplantation both for patients of European origin and for patients from ethnic minorities or mixed ancestries. Marseilles Cord Blood Bank works with one university birth clinic caring for a culturally and sociologically diverse population. Stringent French legal restrictions apply to recording the geographic origin of parents. To circumvent this limitation and evaluate the contribution of newly banked cord blood units (CBUs) to increasing HLA diversity, we applied an algorithm that allows for the determination of parents' putative haplotypes and thus grossly deduce information on their ancestry. Generic resolution HLA-A, HLA-B, and allelic resolution HLA-DRB1 genotyping for 328 CBUs and 2691 unrelated donors (UDs) between January 2009 and May 2012 were performed. Enrichment from international CBU registry with nonreferenced generic HLA-A, HLA-B, and allelic HLA-DRB1 phenotypes was compared between CBUs identified with one or two non-European haplotypes and CBUs identified with two European haplotypes. Marseilles CBUs display an increased proportion of HLA antigens frequently expressed in African populations compared to UDs. Whereas 93% of 199 CBUs identified with one or two non-European haplotypes enrich international CBU registry, this result is reduced to 42% for the 129 CBUs identified with two European haplotypes. This study supports a new method to assess HLA diversity. However, such an increased of HLA diversity raises questions about frequencies of CBUs released and clinical relevance from their uses.
    Transfusion 08/2013; · 3.53 Impact Factor
  • Experimental hematology 02/2013; · 3.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study examines the long-term outcomes of a cohort of patients with myeloma who were treated with reduced-intensity conditioning (RIC) regimens after a minimum follow-up of 5 years at our centre. A total of 53 patients with multiple myeloma (MM) who received allogeneic hematopoietic stem-cell transplantation (Allo-SCT) between January 2000 and January 2007 were identified. The median follow-up of living patients was 84 months (51-141). The median age of the MM patients was 50 (28-70) years. Fifty-one patients (96%) received a transplant from a sibling donor. The median time between diagnosis and Allo-SCT was 34 months (6-161), and the median time between auto-SCT and Allo-SCT was 10 months (1-89). Fifty-one patients (96%) received at least one auto-SCT; 24 patients (45%) received a tandem auto-Allo-SCT. At last follow-up, 21 patients (40%) are alive > 5 years post RIC Allo-SCT. At last follow-up, 14 (26%) are in first complete remission (CR), and four patients (8%) in second CR after donor lymphocyte infusion or re-induction with one of the new anti-myeloma drugs (bortezomib or lenalidomide) after Allo-SCT. Eight patients (38%) among these long survivors received one of these new drugs as induction or relapse treatment before Allo-SCT. Disease status and occurrence of cGvHD were significantly associated with progression-free survival (PFS); hazard ratio (HR) = 0.62 (0.30-1.29, P = 0.20). Acute GvHD was correlated with higher transplant-related mortality; HR = 4.19 (1.05-16.77, P = 0.04). No variables were associated with overall survival (OS). In conclusion, we observe that long-term disease control can be expected in a subset of MM patients undergoing RIC Allo-SCT. After 10 years, the OS and PFS were 32% and 24%, respectively. The PFS curve after Allo-SCT stabilizes in time with a plateau after 6 years post Allo-SCT. Am. J. Hematol. 00:000-000, 2013. © 2013 Wiley Periodicals, Inc.
    American Journal of Hematology 02/2013; · 4.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the attempt to harmonize clinical practices between different French transplantation centers, the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC) set up the third annual series of workshops which brought together practitioners from all member centers and took place in October 2012 in Lille. Here we report our results and recommendations regarding the choice of optimal unrelated cord blood unit in terms of cell dose, HLA-matching and other characteristics.
    Pathologie Biologie 01/2013; 61(4):147–148. · 1.67 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Scope of the study was to investigate the impact of pre-transplant CMV serostatus of the donor and/or recipient on the outcome of patients undergoing allogeneic hematopoietic stem cell transplantation (Allo-SCT) for Multiple Myeloma (MM). To our knowledge no data are available in the literature about this issue. We retrospectively followed 99 consecutive patients who underwent reduced-intensity conditioning (RIC) Allo-SCT for MM in our cancer center at Marseille between January 2000 and January 2012. Based upon CMV serostatus, patients were classified as low risk (donor [D]-/recipient [R] -) 17 patients (17.1%), intermediate risk (D+/R) 14 patients (14.1%), or high risk - either (D-/R+) 31 patients (31.3%) or (D+/R+), 37 patients (37.3%). Cumulative incidence of CMV reactivation was 39% with a median time of 61 days (26-318). Three patients (3%) developed CMV disease. Two factors were associated with CMV reactivation: CMV serostatus group (low: 0% vs. intermediate: 29% vs. high: 50%; p=0.001) and the presence of grade II-IV acute GvHD (Hazard Ratio: HR=2.1 [1.1-3.9]). Thirty-six of the 39 patients (92%) with CMV reactivation did not present positive detection of CMV after a 21-day median duration preemptive treatment with ganciclovir. Cumulative incidence of day 100 grade II-IV acute GvHD, 1-year chronic GvHD and day 100 transplantation related mortality (TRM) were 37%, 36% and 9%, respectively. CMV reactivation and serostatus were not associated with increased GvHD and TRM or short survival. Only the presence of acute GvHD as a time dependent variable was significantly associated with increased TRM (p=0.005). Two-year overall and progression free survival were 56% and 34%, respectively. Donor and recipient CMV serostatus and acute GvHD are independent factors for increased CMV reactivation in high-risk MM patients undergoing RIC Allo-SCT. However, we did not find any influence of CMV reactivation on post transplantation outcome. CMV monitoring and pre-emptive treatment strategy could in part explain these results. Novel prophylactic measures such as immunotherapy and drug prophylaxis need to be considered in this group of patients, warranting further prospective studies.
    Mediterranean Journal of Hematology and Infectious Diseases 01/2013; 5(1):e2013026.
  • [Show abstract] [Hide abstract]
    ABSTRACT: We analyzed 113 patients with lymphoma who underwent allogeneic transplantation with reduced-intensity conditioning (allo-RIC) regimens at a single institution, from February 2001 through November 2009, searching for factors predictive of the outcome. At the time of transplantation, 60% of patients were in CR, 29% in PR and 11% had progressive or stable disease. At a median follow-up of 34 months (confidence interval (CI) 17-45), the 3-year OS and PFS were 59% (CI 48-68%) and 51% (CI 41-61%), respectively. The 100-day and 2-year nonrelapse mortalities (NRM) were 6% and 28% (CI 20-35%), respectively. Grade II-IV acute GVHD (aGVHD) incidence was 38%, and the global incidence of chronic GVHD was 33%. In univariate analysis, OS was influenced by disease status before allo-RIC; aGVHD negatively affected on survival. Similarly, PFS was influenced only by disease status. Histological subtype did not affect OS or PFS. We conclude that disease status at the time of transplantation significantly influences survival in patients receiving allo-RIC for lymphoma, whereas histological subtype does not. This reinforces the need to administer more effective debulking treatments to lymphoma patients, for optimal benefit of allogeneic immune recognition of minimal residual disease, independently from lymphoma histology.Bone Marrow Transplantation advance online publication, 10 December 2012; doi:10.1038/bmt.2012.225.
    Bone marrow transplantation 12/2012; · 3.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Donor lymphocyte infusions (DLI) can induce remission in patients with hematologic malignancies who relapse after allogeneic stem cell transplantation. However, graft-vs-host disease (GVHD) remains a major complication of this strategy. We have used escalating doses of DLI for many years, and wanted to assess the risk factors for GVHD and transplant-related mortality as well as disease outcomes according to the reason for DLI. We analyzed 65 patients who received a total of 111 DLI for different reasons and at different intervals after transplantation. Median number of DLI was 2 (range, 1-4), median interval between transplantation and DLI was 9 months (range, 1-41 months) and median number of infused CD3(+) cells/kg recipient body weight was 2.5 × 10(7) (range, 1 × 10(6)-11.8 × 10(7)). Reasons for DLI were relapse or progression in 37 patients (57%), residual disease in 15 patients (23%), and persistence of mixed chimerism in 13 patients (20%). Seven patients (11%) developed acute GVHD grade II to IV and 5 patients (8%) developed extensive chronic GVHD. In univariate analysis, we could identify a transplantation-DLI interval ≤6 months, the dose of DLI (≥1 × 10(7)), and DLI number as predictive factors of GVHD. In multivariate analysis, these results were confirmed only for the transplantation-DLI interval (hazard ratio = 19.48; 2.23-170.34; p = 0.007). Our findings indicate that this form of adoptive immunotherapy is well tolerated and induces a low incidence of GVHD and transplant-related mortality, supporting further investigation as an upfront modality to enhance the graft-vs-tumor response in high-risk patients.
    Experimental hematology 09/2012; · 3.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The monitoring of chimerism is a standard procedure to assess engraftment and achievement of full donor lymphoid cells after reduced intensity conditioning (RIC) stem cell transplantation (Allo-SCT). However, there is no consensus on when and how often to monitor post-transplant chimerism. We retrospectively analyzed our experience regarding the impact of acute graft versus host disease (GVHD) for the prediction of allograft chimerism. One-hundred-and-fifteen patients transplanted between 2001 and 2010 were identified. This group included 57 females and 58 males with a median age of 50 years (range: 26-68). Patients evaluated in this study were adult patients with hematologic malignancies, who received transplants from an HLA-matched sibling donor or matched unrelated donor (MUD) at allele level so-called 10/10, and received the RIC regimen including fludarabine/busulfan and anti-thymoglobulin (ATG). Mixed T-cell chimerism was defined as between 5 and 94% recipient cells, and full chimerism was defined as the presence of more than 95% donor T-cell chimerism (TCC). Full donor TCC was achieved in 93 patients (81%) at a median of 77 days (range: 30-120) post-transplant. The cumulative incidence of Grade 2-4 GVHD in our population was 25% (95% CI 17-34). The analysis of the population of patients with acute GVHD grade ≥2 showed that at day 120 after Allo-SCT they all had a total full donor TCC. On the other hand, 78 (68%) patients without acute GVHD grade ≥2 presented with mixed chimerism (p = 0.002) on day 120 post-transplant. Interestingly, patients who received ATG 5 mg/kg obtained a higher probability of complete chimerism compared with those receiving 2.5 mg/kg (p = 0.03). In conclusion, our study demonstrates that acute GVHD was predictive of full donor TCC after RIC Allo-SCT. Therefore, our data may challenge the concept of the frequent or close monitoring of donor chimerism in some patients with ongoing acute GVHD. However, chimerism testing could represent an attractive modality for minimal residual disease detection or for impeding relapse warranting further prospective studies. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.
    American Journal of Hematology 08/2012; · 4.00 Impact Factor

Publication Stats

98 Citations
83.06 Total Impact Points

Institutions

  • 2005–2014
    • Institut Paoli Calmettes
      • Cancer Research Center of Marseille (CRCM)
      Marsiglia, Provence-Alpes-Côte d'Azur, France
  • 2013
    • Aix-Marseille Université
      Marsiglia, Provence-Alpes-Côte d'Azur, France
  • 2007
    • University of Texas MD Anderson Cancer Center
      Houston, Texas, United States
    • Institut de Génétique et de Biologie Moléculaire et Cellulaire
      Strasburg, Alsace, France